Suscribirse

De-implementation strategy to reduce inappropriate use of intravenous and urinary catheters (RICAT): a multicentre, prospective, interrupted time-series and before and after study - 21/07/20

Doi : 10.1016/S1473-3099(19)30709-1 
Bart J Laan, MD a, , Jolanda M Maaskant, PhD b, Ingrid J B Spijkerman, PhD c, Marjon J Borgert, PhD d, Mieke H Godfried, PhD d, Berend C Pasmooij d, Brent C Opmeer, PhD e, Margreet C Vos, ProfPhD f, Suzanne E Geerlings, ProfPhD a
a Infectious Diseases, Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands 
b Clinical Epidemiology, Biostatistics, and Bioinformatics, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands 
c Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands 
d Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands 
e Clinical Research Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands 
f Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, Netherlands 

* Correspondence to: Mr Bart J Laan, Internal Medicine, Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam 1105 AZ, Netherlands Internal Medicine Infectious Diseases Amsterdam UMC University of Amsterdam Amsterdam AZ 1105 Netherlands

Summary

Background

Catheter-associated bloodstream infections and urinary tract infections are frequently encountered health care-associated infections. We aimed to reduce inappropriate use of catheters to reduce health care-associated infections.

Methods

In this multicentre, interrupted time-series and before and after study, we introduced a de-implementation strategy with multifaceted interventions in seven hospitals in the Netherlands. Adult patients admitted to internal medicine, gastroenterology, geriatic, oncology, or pulmonology wards, and non-surgical acute admission units, and who had a (central or peripheral) venous or urinary catheter were eligible for inclusion. One of the interventions was that nurses in the participating wards attended educational meetings on appropriate catheter use. Data on catheter use were collected every 2 weeks by the primary research physician during the baseline period (7 months) and intervention period (7 months), which were separated by a 5 month transition period. The primary outcomes were percentages of short peripheral intravenous catheters and urinary catheters used inappropriately on the days of data collection. Indications for catheter use were based on international guidelines. This study is registered with Netherlands Trial Register, NL5438.

Findings

Between Sept 1, 2016, and April 1, 2018, we screened 6157 patients for inclusion, of whom 5696 were enrolled: 2650 patients in the baseline group, and 3046 in the intervention group. Inappropriate use of peripheral intravenous catheters occurred in 366 (22·0%, 95% CI 20·0 to 24·0) of 1665 patients in the baseline group and in 275 (14·4%, 12·8 to 16·0) of 1912 patients in the intervention group (incidence rate ratio [IRR] 0·65, 95% CI 0·56 to 0·77, p<0·0001). Time-series analyses showed an absolute reduction in inappropriate use of peripheral intravenous catheters from baseline to intervention periods of 6·65% (95% CI 2·47 to 10·82, p=0·011). Inappropriate use of urinary catheters occurred in 105 (32·4%, 95% CI 27·3 to 37·8) of 324 patients in the baseline group compared with 96 (24·1%, 20·0 to 28·6) of 398 patients in the intervention group (IRR 0·74, 95% CI 0·56 to 0·98, p=0·013). Time-series analyses showed an absolute reduction in inappropriate use of urinary catheters of 6·34% (95% CI −12·46 to 25·13, p=0·524).

Interpretation

Our de-implementation strategy reduced inappropriate use of short peripheral intravenous catheters in patients who were not in the intensive care unit. The reduction of inappropriate use of urinary catheters was substantial, yet not statistically significant in time-series analysis due to a small sample size. The strategy appears well suited for broad-scale implementation to reduce health care-associated infections.

Funding

Netherlands Organisation for Health Research and Development.

El texto completo de este artículo está disponible en PDF.

Esquema


© 2020  Elsevier Ltd. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 20 - N° 7

P. 864-872 - juillet 2020 Regresar al número
Artículo precedente Artículo precedente
  • Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial
  • Michelle J Groome, Lee Fairlie, Julie Morrison, Alan Fix, Anthonet Koen, Maysseb Masenya, Lisa Jose, Shabir A Madhi, Nicola Page, Monica McNeal, Len Dally, Iksung Cho, Maureen Power, Jorge Flores, Stanley Cryz
| Artículo siguiente Artículo siguiente
  • Pregnancy and breastfeeding in the context of Ebola: a systematic review
  • Megan E Foeller, Carolina Carvalho Ribeiro do Valle, Timothy M Foeller, Olufemi T Oladapo, Elin Roos, Anna E Thorson

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.